Iovance Biotherapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell IOVA and other ETFs, options, and stocks.

About IOVA

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. 

CEO
Frederick G. Vogt
CEOFrederick G. Vogt
Employees
838
Employees838
Headquarters
San Carlos, California
HeadquartersSan Carlos, California
Founded
2007
Founded2007
Employees
838
Employees838

IOVA Key Statistics

Market cap
940.81M
Market cap940.81M
Price-Earnings ratio
-1.96
Price-Earnings ratio-1.96
Dividend yield
Dividend yield
Average volume
11.48M
Average volume11.48M
High today
$2.40
High today$2.40
Low today
$2.32
Low today$2.32
Open price
$2.35
Open price$2.35
Volume
7.58M
Volume7.58M
52 Week high
$6.50
52 Week high$6.50
52 Week low
$1.64
52 Week low$1.64

Stock Snapshot

With a market cap of 940.81M, Iovance Biotherapeutics(IOVA) trades at $2.35. The stock has a price-to-earnings ratio of -1.96.

During the trading session on 2026-01-14, Iovance Biotherapeutics(IOVA) shares reached a daily high of $2.40 and a low of $2.32. At a current price of $2.35, the stock is +1.3% higher than the low and still -2.1% under the high.

Trading volume for Iovance Biotherapeutics(IOVA) stock has reached 7.58M, versus its average volume of 11.48M.

The stock's 52-week range extends from a low of $1.64 to a high of $6.50.

The stock's 52-week range extends from a low of $1.64 to a high of $6.50.

IOVA News

Simply Wall St 2d
The Bull Case For Iovance Biotherapeutics Could Change Following Reaffirmed 2025 Guidance And TIL Scale-Up

Iovance Biotherapeutics recently reaffirmed that it expects to meet its earlier 2025 revenue guidance of US$250 million to US$300 million, while reporting that...

The Bull Case For Iovance Biotherapeutics Could Change Following Reaffirmed 2025 Guidance And TIL Scale-Up
TipRanks 6d
Iovance Highlights Amtagvi Momentum and Confirms 2025 Guidance

Claim 70% Off TipRanks Premium Iovance Biotherapeutics ( (IOVA) ) just unveiled an announcement. On January 9, 2026, Iovance Biotherapeutics updated its corpo...

Analyst ratings

58%

of 12 ratings
Buy
58.3%
Hold
33.3%
Sell
8.3%

People also own

Based on the portfolios of people who own IOVA. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the .